Did You Experience Stomach Issues After Taking Semaglutide?
A medication used for weight loss and the treatment of type 2 diabetes, semaglutide has been linked to severe gastrointestinal problems, including vomiting and stomach paralysis. Affected patients may consider pursuing lawsuits against the manufacturer, alleging that they downplayed the severity of the medication’s side effects and failed to provide adequate warnings.
Start My Semaglutide Lawsuit Claim Now
Semaglutide Lawsuit
A medication used for weight loss and the treatment of type 2 diabetes, semaglutide has been linked to severe gastrointestinal problems, including vomiting and stomach paralysis. Affected patients may consider pursuing lawsuits against the manufacturer, alleging that they downplayed the severity of the medication's side effects and failed to provide adequate warnings.
Semaglutide, developed by Danish pharmaceutical company Novo Nordisk, is a medication that has gained popularity in recent years for its dual purpose in treating diabetes and aiding in weight loss. However, serious concerns have been raised about the potential risk of side effects associated with medications containing the active ingredient semaglutide, including Ozempic (a type 2 diabetes drug) and Wegovy (a weight-loss drug). If you or someone you love took Ozempic, Wegovy, or another semaglutide medication and subsequently experienced complications like persistent vomiting, stomach paralysis (gastroparesis), or the need for surgery, do not hesitate to speak to an experienced semaglutide injury attorney about your legal options. You may have grounds to file a semaglutide lawsuit against Novo Nordisk in order to pursue financial compensation for your injuries.
What is Semaglutide?
Marketed under various brand names such as Ozempic and Wegovy, semaglutide is a GLP-1 receptor agonist. It belongs to a class of drugs known as incretin mimetics, which work by mimicking the action of a naturally occurring hormone called glucagon-like peptide-1 (GLP-1). GLP-1 is produced in the small intestine and plays a crucial role in regulating blood sugar levels by stimulating insulin secretion. Additionally, GLP-1 slows down the emptying of the stomach, which promotes a feeling of fullness and can lead to weight loss. Semaglutide acts by binding to GLP-1 receptors in the body, leading to similar effects as the natural hormone.
Semaglutide Approved for Weight Loss
Initially approved by the U.S. Food and Drug Administration (FDA) in 2017 under the brand name Ozempic, an injectable prescription medication indicated for the treatment of type 2 diabetes, semaglutide has since gained additional approvals for aiding in weight loss. The injectable prescription medication Wegovy (semaglutide) was approved in 2021 for chronic weight management in adults who are obese or those who are overweight and have at least one weight-related condition. However, recent reports have raised concerns about potential side effects associated with the use of semaglutide, particularly gastrointestinal issues such as persistent vomiting, stomach paralysis, and gastroparesis.
Some patients who have taken semaglutide, including the diabetes drug Ozempic or weight-loss drug Wegovy, have reported severe side effects that have the potential to cause significant physical and emotional distress. These side effects include persistent vomiting, stomach paralysis, gastroparesis, and other serious gastrointestinal problems. Some of these symptoms may be severe enough that the affected patient is hospitalized and requires surgery. The gastrointestinal side effects that have been linked to semaglutide use can have a profound impact on patients’ quality of life and overall well-being. The severity and persistence of these side effects may prompt affected individuals to pursue legal action against the manufacturers of semaglutide medications.
Link Between Semaglutide and Gastrointestinal Problems
One of the primary concerns surrounding the use of semaglutide is its potential to cause severe gastrointestinal issues. Studies have shown a link between the use of GLP-1 receptor agonists, including semaglutide, and the development of gastroparesis or stomach paralysis, a condition characterized by delayed stomach emptying. Gastroparesis can lead to symptoms such as nausea, vomiting, bloating, and abdominal pain. The exact mechanism by which semaglutide and other GLP-1 receptor agonists contribute to the development of gastroparesis is not fully understood. However, it is believed that the drugs may affect the nerves in the stomach, slowing down muscle contractions and impeding the normal movement of food through the digestive system. This can result in the accumulation of food in the stomach, which can lead to gastroparesis.
Pursuing Lawsuits for Semaglutide-Related Injuries
Patients who have experienced persistent vomiting, stomach paralysis, gastroparesis, or other gastrointestinal problems after taking semaglutide may have legal recourse. By filing a product liability lawsuit against the manufacturer of semaglutide drugs like Ozempic or Wegovy, affected individuals can seek compensation for their injuries, medical expenses, pain and suffering, and other damages.
Semaglutide Lawsuits
Lawsuits against Novo Nordisk for injuries allegedly caused by Ozempic, Wegovy, or another semaglutide medication may be based on claims of negligence, failure to warn, and defective product design. Plaintiffs may argue that the drug manufacturer knew or should have known about the potential risks and side effects associated with semaglutide but failed to adequately warn patients and healthcare providers.
Semaglutide Lawsuit Alleges Stomach Paralysis
To pursue a semaglutide lawsuit, individuals should consult with an experienced product liability attorney who specializes in handling drug injury claims. A knowledgeable semaglutide attorney can assess the merits of the case, gather evidence, and guide plaintiffs through the legal process.
Lawsuits Against Semaglutide for Stomach Paralysis
One specific gastrointestinal side effect that will likely be the basis for many semaglutide lawsuits is stomach paralysis, also known as gastroparesis. Stomach paralysis occurs when the normal contractions of the stomach muscles slow down or cease, leading to the inability to properly digest food and move it through the digestive system. Individuals who have developed stomach paralysis after taking semaglutide may experience symptoms such as severe vomiting, stomach pain, bloating, and an inability to eat. In some cases, the condition becomes so debilitating that surgical intervention is required.
Novo Nordisk Accused of Failure to Warn in Ozempic Claim
Lawsuits against Novo Nordisk for stomach paralysis injuries will likely claim that the drug manufacturer failed to adequately warn patients and healthcare providers about the risk of developing this serious gastrointestinal condition. In one recent semaglutide lawsuit filed in August 2023, plaintiff Jaclyn Bjorklund alleges that Novo Nordisk and Eli Lilly failed to provide adequate warnings about the potential risks of taking Ozempic and another blockbuster diabetes drug called Mounjaro. According to Bjorklund, she was prescribed Ozempic and Mounjaro by her doctor and subsequently experienced severe vomiting, gastrointestinal burning, stomach pain, and multiple hospitalizations due to gastrointestinal problems. Bjorklund also states in her complaint that excessive vomiting from taking Ozempic and Mounjaro caused her to lose some of her teeth.
Semaglutide Side Effect Studies
Several scientific studies have been conducted to investigate the potential side effects of GLP-1 receptor agonists like semaglutide and their association with gastrointestinal problems. These studies have provided valuable insights into the risks and complications that can arise from the use of this medication. These studies contribute to the growing body of evidence linking semaglutide and similar drugs to gastrointestinal problems, providing valuable support for individuals pursuing legal action against the manufacturers.
Study: GLP-1 Analogues Linked to Bile Duct and Gallbladder Disease
A study published in the medical journal JAMA Internal Medicine links GLP-1 analogues to an increased risk of bile duct and gallbladder disease.October 2016Semaglutide/Cholelithiasis Issue Highlighted
According to research published in the journal Diabetes, Obesity & Metabolism, GLP-1 receptor agonist medications are associated with a risk of cholelithiasis (gallstones).September 2017Meta-Analysis Identifies Risks of GLP1-RA
A meta-analysis published in the journal Diabetes Research and Clinical Practice states that using GLP-1 receptor agonists (GLP1-RA) significantly increases the risk of cholelithiasis.February 2020History-Taking Reveals Cause of Gastroparesis to Be Medication-Induced
In a case report republished in the Journal of Investigative Medicine High Impact Case Reports, there are two cases of medication-induced gastroparesis that were initially diagnosed as diabetic gastroparesis. The researchers state that “thorough history taking revealed the cause [of the gastroparesis] to be medication induced.” They also wrote that “Repeat studies following medication discontinuation revealed improvement in symptoms and resolution of gastroparesis.”October 2021GLP1-RAs Tied to Gallbladder and Biliary Diseases
A GLP-1-1 RA study published in JAMA Internal Medicine reports that the use of GLP-1 RAs is tied to an increased risk of gallbladder or biliary diseases. The study authors find that the risk of these side effects increases when the medications are used at higher doses, for longer periods of time, or for weight-loss purposes.March 2022Semaglutide Linked to Gastrointestinal Adverse Events: Study
Research published in the journal Frontiers in Endocrinology finds that "GLP-1 RA [like Ozempic] were significantly associated with gastrointestinal AEs [adverse events], and the association was further attributed to liraglutide, dulaglutide, and semaglutide." The researchers also conclude that "semaglutide had the greatest risk of nausea, diarrhea, vomiting, constipation, and pancreatitis [...]"
December 2022Gastroparesis Side Effects from GLP-a Agonists for Weight Loss
A study comparing the use of the GLP-1 agonists liraglutide and semaglutide to bupropion-naltrexone, indicates that "use of GLP-1 agonists for weight loss compared with use of bupropion-naltrexone was associated with increased risk of pancreatitis, gastroparesis, and bowel obstruction [...]"
October 2023Non Semaglutide Lawsuit Drugs
Alleged Side Effects Leading to a Semaglutide Lawsuit
Start My Semaglutide Lawsuit Claim Now
Why We Think the Manufacturer Should be Held Liable
When it comes to pharmaceutical drugs like semaglutide, manufacturers have a responsibility to ensure the safety of their drugs and to provide accurate and adequate warnings about potential side effects. If a manufacturer fails to fulfill this duty and individuals suffer harm as a result, they may be held liable for their negligence. In the case of semaglutide, plaintiffs in lawsuits argue that the manufacturer knew or should have known about the risks of gastrointestinal problems, including stomach paralysis and gastroparesis, associated with the drug. By failing to warn patients and healthcare providers adequately, the manufacturers have been accused of putting individuals at risk and causing them unnecessary harm.
What should you do? If you suffered from stomach paralysis, gastroparesis, or another alleged drug injury, you should contact a lawyer as soon as possible to discuss filing a semaglutide lawsuit.
Start Your Claim Now!
Holding Novo Nordisk accountable for stomach paralysis (gastroparesis), persistent vomiting, hospitalization, and other alleged drug-related injuries through legal action can not only provide compensation for affected individuals but also serve as a deterrent for future negligence in the pharmaceutical industry. It sends a message that drug manufacturers must prioritize patient safety and provide accurate information about the potential risks and side effects of their medications. If you have experienced persistent vomiting, stomach paralysis, gastroparesis, or other gastrointestinal problems after taking semaglutide, it is crucial to consult with an experienced attorney who can guide you through the process of pursuing a lawsuit. Call us today or fill out the form and we can connect you with an attorney who specializes in drug injury claims.
- Fight to Get The Compensation You Deserve
- Experienced Semaglutide Attorneys Within Reach
Related Legal Claim Topics
Gastroparesis Diagnosis Confirmed Through Gastric Emptying Test: Ozempic Lawsuit
Ozempic and Colonoscopy Prep: New Study Highlights Potential Risks
